| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking Cessation | 43 | 2023 | 258 | 6.550 |
Why?
|
| Smoking | 48 | 2022 | 625 | 6.330 |
Why?
|
| Bupropion | 12 | 2023 | 21 | 2.570 |
Why?
|
| Nicotine | 19 | 2018 | 200 | 2.450 |
Why?
|
| Genome-Wide Association Study | 22 | 2023 | 1691 | 2.310 |
Why?
|
| Genetic Variation | 20 | 2022 | 1380 | 2.160 |
Why?
|
| Tobacco Use Disorder | 17 | 2019 | 116 | 2.030 |
Why?
|
| Dopamine Uptake Inhibitors | 7 | 2014 | 44 | 1.760 |
Why?
|
| Pharmacogenetics | 11 | 2024 | 437 | 1.630 |
Why?
|
| Whole Genome Sequencing | 12 | 2022 | 103 | 1.560 |
Why?
|
| Lipids | 4 | 2022 | 275 | 1.360 |
Why?
|
| Polymorphism, Genetic | 14 | 2014 | 824 | 1.340 |
Why?
|
| Genetic Predisposition to Disease | 17 | 2023 | 2360 | 1.300 |
Why?
|
| Polymorphism, Single Nucleotide | 22 | 2023 | 2415 | 1.230 |
Why?
|
| Brain | 9 | 2018 | 2305 | 1.190 |
Why?
|
| Primary Health Care | 5 | 2021 | 352 | 1.160 |
Why?
|
| Bias | 3 | 2018 | 135 | 1.100 |
Why?
|
| Nicotinic Agonists | 6 | 2017 | 74 | 0.990 |
Why?
|
| Humans | 122 | 2024 | 89961 | 0.990 |
Why?
|
| Genotype | 23 | 2021 | 1852 | 0.920 |
Why?
|
| Family Practice | 6 | 2010 | 83 | 0.890 |
Why?
|
| Public Health | 3 | 2016 | 140 | 0.870 |
Why?
|
| Precision Medicine | 7 | 2021 | 413 | 0.860 |
Why?
|
| Community Health Services | 3 | 2013 | 82 | 0.840 |
Why?
|
| Chromosomes, Human, Pair 15 | 4 | 2016 | 66 | 0.840 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 3 | 2008 | 48 | 0.820 |
Why?
|
| Alleles | 13 | 2022 | 1137 | 0.810 |
Why?
|
| Sex Characteristics | 2 | 2018 | 328 | 0.800 |
Why?
|
| Genome, Human | 7 | 2021 | 791 | 0.790 |
Why?
|
| Narcotic Antagonists | 2 | 2014 | 161 | 0.790 |
Why?
|
| Male | 61 | 2024 | 42674 | 0.760 |
Why?
|
| Receptors, Dopamine D2 | 5 | 2009 | 57 | 0.720 |
Why?
|
| Patient Readmission | 1 | 2024 | 355 | 0.720 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 59 | 0.720 |
Why?
|
| Cigarette Smoking | 2 | 2020 | 36 | 0.710 |
Why?
|
| Female | 65 | 2024 | 46587 | 0.710 |
Why?
|
| Smoking Prevention | 3 | 2013 | 45 | 0.700 |
Why?
|
| Genetic Testing | 4 | 2021 | 543 | 0.690 |
Why?
|
| Adult | 48 | 2024 | 26816 | 0.670 |
Why?
|
| Dopamine | 2 | 2013 | 276 | 0.670 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2018 | 3475 | 0.650 |
Why?
|
| Phenotype | 16 | 2022 | 2456 | 0.650 |
Why?
|
| Middle Aged | 42 | 2024 | 26146 | 0.640 |
Why?
|
| Genetic Counseling | 2 | 2018 | 102 | 0.640 |
Why?
|
| Gene Frequency | 12 | 2022 | 687 | 0.640 |
Why?
|
| Sample Size | 7 | 2022 | 125 | 0.630 |
Why?
|
| Genetic Association Studies | 7 | 2021 | 294 | 0.620 |
Why?
|
| Public Health Administration | 2 | 2013 | 18 | 0.620 |
Why?
|
| Evidence-Based Medicine | 6 | 2009 | 435 | 0.610 |
Why?
|
| Receptors, Dopamine D4 | 4 | 2014 | 11 | 0.600 |
Why?
|
| Patient-Centered Care | 2 | 2015 | 210 | 0.600 |
Why?
|
| Cytochrome P-450 CYP2A6 | 6 | 2018 | 9 | 0.600 |
Why?
|
| Neuroimaging | 2 | 2018 | 116 | 0.590 |
Why?
|
| Meta-Analysis as Topic | 3 | 2021 | 81 | 0.550 |
Why?
|
| Genomics | 3 | 2021 | 778 | 0.550 |
Why?
|
| Publication Bias | 2 | 2014 | 13 | 0.550 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2023 | 841 | 0.540 |
Why?
|
| United States | 17 | 2024 | 7108 | 0.520 |
Why?
|
| Smokers | 1 | 2016 | 46 | 0.520 |
Why?
|
| Genetics, Population | 4 | 2021 | 407 | 0.510 |
Why?
|
| Naltrexone | 2 | 2014 | 137 | 0.510 |
Why?
|
| Gene-Environment Interaction | 2 | 2016 | 118 | 0.490 |
Why?
|
| Physicians, Family | 4 | 2018 | 39 | 0.480 |
Why?
|
| Catechol O-Methyltransferase | 4 | 2014 | 69 | 0.470 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 5 | 2012 | 44 | 0.460 |
Why?
|
| Receptors, Nicotinic | 5 | 2018 | 131 | 0.440 |
Why?
|
| Alcohol Drinking | 3 | 2022 | 275 | 0.430 |
Why?
|
| Health Care Reform | 2 | 2013 | 85 | 0.420 |
Why?
|
| Double-Blind Method | 11 | 2014 | 1714 | 0.420 |
Why?
|
| Nerve Tissue Proteins | 6 | 2021 | 511 | 0.420 |
Why?
|
| Mental Disorders | 2 | 2014 | 417 | 0.420 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2655 | 0.420 |
Why?
|
| Aged | 19 | 2024 | 19254 | 0.410 |
Why?
|
| Community Health Planning | 1 | 2012 | 21 | 0.400 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 163 | 0.400 |
Why?
|
| Risk Factors | 11 | 2024 | 5558 | 0.400 |
Why?
|
| Physical Chromosome Mapping | 1 | 2021 | 27 | 0.390 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 2010 | 47 | 0.380 |
Why?
|
| Education, Medical | 3 | 2014 | 243 | 0.380 |
Why?
|
| Cardiovascular Diseases | 4 | 2022 | 716 | 0.370 |
Why?
|
| Genome | 3 | 2022 | 391 | 0.370 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2020 | 21 | 0.370 |
Why?
|
| Apolipoprotein L1 | 1 | 2020 | 7 | 0.370 |
Why?
|
| Blood Platelets | 1 | 2021 | 150 | 0.360 |
Why?
|
| Sickle Cell Trait | 1 | 2020 | 21 | 0.360 |
Why?
|
| Delivery of Health Care | 2 | 2012 | 437 | 0.360 |
Why?
|
| Multifactorial Inheritance | 2 | 2022 | 173 | 0.360 |
Why?
|
| Research Design | 3 | 2014 | 591 | 0.350 |
Why?
|
| Cues | 3 | 2014 | 174 | 0.350 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2021 | 107 | 0.350 |
Why?
|
| HLA Antigens | 1 | 2021 | 227 | 0.350 |
Why?
|
| Lymphoma, B-Cell | 1 | 2011 | 107 | 0.340 |
Why?
|
| Cohort Studies | 5 | 2024 | 2886 | 0.340 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 3022 | 0.340 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 185 | 0.340 |
Why?
|
| Models, Genetic | 3 | 2021 | 948 | 0.340 |
Why?
|
| Cholesterol, LDL | 4 | 2022 | 226 | 0.330 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 3 | 2021 | 25 | 0.330 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 237 | 0.330 |
Why?
|
| Lung Neoplasms | 4 | 2016 | 2370 | 0.330 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 1730 | 0.330 |
Why?
|
| Genetic Loci | 4 | 2022 | 253 | 0.320 |
Why?
|
| Chromosome Mapping | 2 | 2021 | 1074 | 0.320 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2008 | 11 | 0.310 |
Why?
|
| Risk Assessment | 5 | 2018 | 2327 | 0.310 |
Why?
|
| Nortriptyline | 1 | 2008 | 6 | 0.310 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 3678 | 0.300 |
Why?
|
| Education, Medical, Undergraduate | 3 | 2016 | 182 | 0.290 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 222 | 0.290 |
Why?
|
| Computational Biology | 1 | 2021 | 551 | 0.290 |
Why?
|
| Ganglionic Stimulants | 2 | 2004 | 7 | 0.290 |
Why?
|
| Drug Interactions | 2 | 2024 | 244 | 0.290 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2006 | 608 | 0.290 |
Why?
|
| Community Participation | 1 | 2007 | 38 | 0.280 |
Why?
|
| Academic Medical Centers | 2 | 2006 | 384 | 0.280 |
Why?
|
| Achievement | 1 | 2006 | 29 | 0.270 |
Why?
|
| Treatment Outcome | 13 | 2017 | 8273 | 0.270 |
Why?
|
| Young Adult | 9 | 2022 | 6409 | 0.260 |
Why?
|
| Tobacco Use | 2 | 2023 | 27 | 0.260 |
Why?
|
| Genetic Markers | 3 | 2019 | 476 | 0.260 |
Why?
|
| Algorithms | 2 | 2021 | 1913 | 0.260 |
Why?
|
| Coronary Disease | 2 | 2008 | 260 | 0.250 |
Why?
|
| Retrospective Studies | 5 | 2024 | 9210 | 0.250 |
Why?
|
| Kidney | 1 | 2020 | 1148 | 0.250 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2005 | 4 | 0.250 |
Why?
|
| Basal Ganglia | 1 | 2005 | 46 | 0.250 |
Why?
|
| Adolescent | 7 | 2022 | 9340 | 0.240 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 490 | 0.240 |
Why?
|
| Signal Transduction | 3 | 2021 | 3404 | 0.230 |
Why?
|
| Nucleus Accumbens | 1 | 2005 | 113 | 0.230 |
Why?
|
| Proteins | 1 | 2010 | 787 | 0.230 |
Why?
|
| Administration, Cutaneous | 6 | 2014 | 59 | 0.230 |
Why?
|
| Behavior, Addictive | 2 | 2009 | 134 | 0.230 |
Why?
|
| Folic Acid Deficiency | 1 | 2003 | 7 | 0.220 |
Why?
|
| Hematinics | 1 | 2003 | 11 | 0.220 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 103 | 0.220 |
Why?
|
| Haplotypes | 4 | 2021 | 637 | 0.220 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2003 | 25 | 0.210 |
Why?
|
| Folic Acid | 1 | 2003 | 63 | 0.210 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2002 | 1 | 0.210 |
Why?
|
| Problem Solving | 1 | 2013 | 54 | 0.210 |
Why?
|
| Drug Repositioning | 1 | 2023 | 23 | 0.210 |
Why?
|
| Linkage Disequilibrium | 3 | 2022 | 477 | 0.210 |
Why?
|
| Internationality | 1 | 2022 | 70 | 0.210 |
Why?
|
| HIV Infections | 1 | 2021 | 846 | 0.200 |
Why?
|
| Mobile Applications | 1 | 2023 | 71 | 0.200 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 131 | 0.200 |
Why?
|
| Prospective Studies | 6 | 2022 | 4329 | 0.200 |
Why?
|
| Teaching | 1 | 2003 | 147 | 0.200 |
Why?
|
| Visual Perception | 1 | 2005 | 326 | 0.200 |
Why?
|
| Biomedical Research | 1 | 2006 | 405 | 0.200 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 179 | 0.200 |
Why?
|
| Statistics as Topic | 2 | 2013 | 234 | 0.200 |
Why?
|
| Models, Theoretical | 1 | 2004 | 493 | 0.190 |
Why?
|
| Metabolomics | 2 | 2022 | 76 | 0.190 |
Why?
|
| Quantitative Trait Loci | 4 | 2021 | 615 | 0.190 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2022 | 73 | 0.190 |
Why?
|
| Sensitivity and Specificity | 3 | 2021 | 2018 | 0.190 |
Why?
|
| Exome | 2 | 2019 | 131 | 0.190 |
Why?
|
| Minisatellite Repeats | 2 | 2014 | 24 | 0.190 |
Why?
|
| Physician-Patient Relations | 4 | 2020 | 625 | 0.180 |
Why?
|
| Marketing of Health Services | 1 | 2001 | 15 | 0.180 |
Why?
|
| Counseling | 4 | 2022 | 166 | 0.180 |
Why?
|
| Financial Management | 1 | 2001 | 21 | 0.180 |
Why?
|
| Chromosomes, Human, X | 1 | 2021 | 55 | 0.180 |
Why?
|
| Faculty | 1 | 2001 | 33 | 0.180 |
Why?
|
| Transcriptome | 2 | 2023 | 661 | 0.180 |
Why?
|
| Mass Media | 1 | 2001 | 27 | 0.180 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2013 | 36 | 0.180 |
Why?
|
| Women's Health | 3 | 2020 | 103 | 0.180 |
Why?
|
| Biomarkers | 4 | 2021 | 1778 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 3 | 2020 | 919 | 0.180 |
Why?
|
| Respiratory Mucosa | 1 | 2021 | 88 | 0.180 |
Why?
|
| Proteome | 1 | 2021 | 135 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2001 | 107 | 0.180 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 654 | 0.180 |
Why?
|
| Environmental Exposure | 1 | 2003 | 334 | 0.180 |
Why?
|
| Amish | 1 | 2020 | 6 | 0.170 |
Why?
|
| Bronchi | 1 | 2021 | 230 | 0.170 |
Why?
|
| Mammography | 1 | 2003 | 475 | 0.170 |
Why?
|
| Body Temperature | 1 | 2020 | 125 | 0.170 |
Why?
|
| Asthma | 3 | 2021 | 984 | 0.170 |
Why?
|
| Clinical Clerkship | 5 | 2016 | 118 | 0.170 |
Why?
|
| Vital Capacity | 1 | 2019 | 69 | 0.160 |
Why?
|
| Forced Expiratory Volume | 1 | 2019 | 126 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 432 | 0.160 |
Why?
|
| Interferon Regulatory Factors | 1 | 2019 | 70 | 0.160 |
Why?
|
| Odds Ratio | 4 | 2012 | 682 | 0.160 |
Why?
|
| Prevalence | 3 | 2022 | 1250 | 0.160 |
Why?
|
| Rhode Island | 3 | 2007 | 10 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 166 | 0.160 |
Why?
|
| Minority Groups | 1 | 2020 | 147 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2018 | 693 | 0.160 |
Why?
|
| Curriculum | 3 | 2016 | 573 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 1134 | 0.160 |
Why?
|
| Mass Screening | 1 | 2003 | 647 | 0.160 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 1983 | 0.150 |
Why?
|
| Lipoprotein(a) | 1 | 2018 | 30 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 420 | 0.150 |
Why?
|
| Psychology | 1 | 2018 | 25 | 0.150 |
Why?
|
| Insurance | 1 | 2018 | 12 | 0.150 |
Why?
|
| Illinois | 1 | 2020 | 485 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2022 | 539 | 0.150 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 1704 | 0.150 |
Why?
|
| Massachusetts | 1 | 2017 | 33 | 0.150 |
Why?
|
| Base Sequence | 3 | 2021 | 2329 | 0.150 |
Why?
|
| Pandemics | 2 | 2022 | 778 | 0.140 |
Why?
|
| Time | 1 | 2017 | 76 | 0.140 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 181 | 0.140 |
Why?
|
| Age Factors | 2 | 2020 | 1880 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2002 | 798 | 0.140 |
Why?
|
| Organ Size | 1 | 2017 | 372 | 0.140 |
Why?
|
| Clinical Competence | 4 | 2016 | 796 | 0.140 |
Why?
|
| San Francisco | 1 | 2016 | 24 | 0.140 |
Why?
|
| Physician's Role | 1 | 2018 | 176 | 0.130 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 6783 | 0.130 |
Why?
|
| Genes, Modifier | 1 | 2016 | 5 | 0.130 |
Why?
|
| Buprenorphine | 2 | 2014 | 41 | 0.130 |
Why?
|
| Comorbidity | 1 | 2020 | 953 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2020 | 906 | 0.130 |
Why?
|
| Internship and Residency | 2 | 2006 | 1062 | 0.120 |
Why?
|
| DNA Mutational Analysis | 2 | 2020 | 528 | 0.120 |
Why?
|
| History, 21st Century | 2 | 2006 | 184 | 0.120 |
Why?
|
| Cognitive Science | 1 | 2014 | 3 | 0.120 |
Why?
|
| Reference Standards | 2 | 2021 | 144 | 0.120 |
Why?
|
| Students, Medical | 3 | 2016 | 425 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2019 | 866 | 0.110 |
Why?
|
| Overweight | 1 | 2014 | 119 | 0.110 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2767 | 0.110 |
Why?
|
| Databases, Bibliographic | 1 | 2013 | 17 | 0.110 |
Why?
|
| Tandem Repeat Sequences | 1 | 2013 | 29 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 521 | 0.110 |
Why?
|
| Alzheimer Disease | 1 | 2018 | 515 | 0.110 |
Why?
|
| Postmenopause | 1 | 2014 | 102 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 262 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 869 | 0.110 |
Why?
|
| Naloxone | 1 | 2013 | 68 | 0.110 |
Why?
|
| Mutation | 3 | 2020 | 4168 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2016 | 384 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2012 | 47 | 0.100 |
Why?
|
| Obesity, Abdominal | 1 | 2012 | 8 | 0.100 |
Why?
|
| Computer Simulation | 2 | 2021 | 1102 | 0.100 |
Why?
|
| History, 20th Century | 2 | 2006 | 314 | 0.100 |
Why?
|
| Drug Discovery | 1 | 2013 | 107 | 0.100 |
Why?
|
| Varenicline | 2 | 2023 | 15 | 0.100 |
Why?
|
| Genes, Synthetic | 1 | 2011 | 7 | 0.100 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2012 | 78 | 0.100 |
Why?
|
| Proteoglycans | 1 | 2012 | 123 | 0.100 |
Why?
|
| Thrombophilia | 1 | 2011 | 23 | 0.100 |
Why?
|
| Platelet Function Tests | 1 | 2021 | 11 | 0.100 |
Why?
|
| K562 Cells | 1 | 2021 | 44 | 0.090 |
Why?
|
| Platelet Aggregation | 1 | 2021 | 44 | 0.090 |
Why?
|
| RGS Proteins | 1 | 2021 | 19 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1866 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2014 | 776 | 0.090 |
Why?
|
| Viral Load | 1 | 2021 | 145 | 0.090 |
Why?
|
| Saliva | 1 | 2011 | 124 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 2021 | 145 | 0.090 |
Why?
|
| Albuminuria | 1 | 2020 | 48 | 0.090 |
Why?
|
| Amino Acids | 1 | 2021 | 246 | 0.090 |
Why?
|
| HIV-1 | 1 | 2021 | 164 | 0.090 |
Why?
|
| Verbal Learning | 1 | 2010 | 29 | 0.090 |
Why?
|
| Melanoma | 1 | 2015 | 471 | 0.090 |
Why?
|
| Incidence | 2 | 2020 | 1603 | 0.090 |
Why?
|
| Health Policy | 1 | 2012 | 188 | 0.090 |
Why?
|
| Exons | 2 | 2014 | 453 | 0.090 |
Why?
|
| Research | 1 | 2021 | 251 | 0.090 |
Why?
|
| Europe | 2 | 2022 | 324 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2011 | 142 | 0.090 |
Why?
|
| Reward | 1 | 2012 | 193 | 0.090 |
Why?
|
| Creatinine | 1 | 2020 | 294 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 288 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 198 | 0.080 |
Why?
|
| Brain Mapping | 3 | 2012 | 570 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 598 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 277 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1452 | 0.080 |
Why?
|
| Time Factors | 4 | 2017 | 5358 | 0.080 |
Why?
|
| Heterozygote | 2 | 2021 | 373 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2012 | 1255 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2021 | 646 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 338 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2011 | 322 | 0.080 |
Why?
|
| Thrombosis | 1 | 2021 | 302 | 0.080 |
Why?
|
| Genes, BRCA1 | 2 | 2014 | 192 | 0.080 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2007 | 14 | 0.070 |
Why?
|
| Logistic Models | 2 | 2012 | 1214 | 0.070 |
Why?
|
| Preceptorship | 2 | 2013 | 4 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2007 | 221 | 0.070 |
Why?
|
| Selection, Genetic | 1 | 2021 | 515 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1082 | 0.070 |
Why?
|
| Neoplasms | 2 | 2020 | 3065 | 0.070 |
Why?
|
| Genetic Linkage | 1 | 2008 | 624 | 0.070 |
Why?
|
| Software | 1 | 2021 | 669 | 0.070 |
Why?
|
| Memory, Short-Term | 1 | 2010 | 230 | 0.070 |
Why?
|
| Tobacco Products | 2 | 2019 | 64 | 0.070 |
Why?
|
| Decision Making | 1 | 2012 | 670 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2007 | 278 | 0.070 |
Why?
|
| Education | 1 | 2006 | 58 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 1131 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 980 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 785 | 0.070 |
Why?
|
| Child | 3 | 2022 | 7240 | 0.060 |
Why?
|
| Hypertension | 1 | 2012 | 747 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 2000 | 0.060 |
Why?
|
| Gene Expression | 2 | 2021 | 1309 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2008 | 300 | 0.060 |
Why?
|
| Self Efficacy | 2 | 2016 | 57 | 0.060 |
Why?
|
| Germ-Line Mutation | 2 | 2020 | 347 | 0.060 |
Why?
|
| United Kingdom | 2 | 2019 | 165 | 0.060 |
Why?
|
| Risk | 2 | 2019 | 657 | 0.060 |
Why?
|
| Pedigree | 2 | 2020 | 969 | 0.060 |
Why?
|
| Drug Design | 1 | 2004 | 126 | 0.060 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 422 | 0.060 |
Why?
|
| Placebos | 1 | 2003 | 211 | 0.050 |
Why?
|
| Negotiating | 1 | 2013 | 20 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 171 | 0.050 |
Why?
|
| Piperazines | 1 | 2005 | 283 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1180 | 0.050 |
Why?
|
| Pyridines | 1 | 2005 | 300 | 0.050 |
Why?
|
| Benchmarking | 1 | 2003 | 79 | 0.050 |
Why?
|
| Neural Tube Defects | 1 | 2003 | 45 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2004 | 222 | 0.050 |
Why?
|
| Politics | 1 | 2013 | 52 | 0.050 |
Why?
|
| Conflict of Interest | 1 | 2013 | 68 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 52 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2003 | 111 | 0.050 |
Why?
|
| Drug Industry | 1 | 2013 | 54 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2002 | 20 | 0.050 |
Why?
|
| Genes, BRCA2 | 1 | 2003 | 161 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 50 | 0.050 |
Why?
|
| Metabolome | 1 | 2022 | 51 | 0.050 |
Why?
|
| Forecasting | 1 | 2013 | 304 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 104 | 0.050 |
Why?
|
| Functional Neuroimaging | 2 | 2012 | 31 | 0.050 |
Why?
|
| Obesity | 2 | 2021 | 972 | 0.050 |
Why?
|
| Subcutaneous Tissue | 1 | 2021 | 10 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 365 | 0.050 |
Why?
|
| Plasma | 1 | 2021 | 51 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2021 | 71 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2021 | 43 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2021 | 32 | 0.050 |
Why?
|
| Protein Binding | 1 | 2005 | 1491 | 0.050 |
Why?
|
| China | 2 | 2012 | 235 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2002 | 184 | 0.050 |
Why?
|
| alpha Karyopherins | 1 | 2020 | 10 | 0.050 |
Why?
|
| Tripartite Motif Proteins | 1 | 2020 | 3 | 0.050 |
Why?
|
| Mental Health | 1 | 2022 | 180 | 0.050 |
Why?
|
| Social Values | 1 | 2001 | 44 | 0.050 |
Why?
|
| Communication | 1 | 2004 | 461 | 0.050 |
Why?
|
| Cell Self Renewal | 1 | 2020 | 20 | 0.050 |
Why?
|
| Quality Control | 1 | 2021 | 117 | 0.050 |
Why?
|
| Population Density | 1 | 2021 | 61 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 46 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2021 | 52 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2677 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 101 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 203 | 0.040 |
Why?
|
| England | 1 | 2000 | 38 | 0.040 |
Why?
|
| House Calls | 1 | 2000 | 9 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 77 | 0.040 |
Why?
|
| Goals | 1 | 2001 | 67 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2020 | 71 | 0.040 |
Why?
|
| Oxygen | 1 | 2005 | 745 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2001 | 88 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 344 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2021 | 128 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2020 | 37 | 0.040 |
Why?
|
| Costa Rica | 1 | 2019 | 15 | 0.040 |
Why?
|
| Professional Competence | 1 | 2020 | 69 | 0.040 |
Why?
|
| Sex Factors | 3 | 2009 | 1075 | 0.040 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2019 | 48 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 303 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 311 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 177 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 469 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2008 | 1055 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 305 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 387 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 68 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2018 | 50 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 264 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2018 | 269 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 665 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2011 | 958 | 0.030 |
Why?
|
| Pregnancy | 1 | 2003 | 3046 | 0.030 |
Why?
|
| Computer-Assisted Instruction | 1 | 2016 | 44 | 0.030 |
Why?
|
| Smoke | 1 | 2015 | 27 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1243 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 206 | 0.030 |
Why?
|
| Models, Educational | 1 | 2014 | 49 | 0.030 |
Why?
|
| Amygdala | 1 | 2014 | 86 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 591 | 0.030 |
Why?
|
| Economics, Behavioral | 1 | 2012 | 7 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 3771 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2013 | 281 | 0.030 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 17 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 95 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 2012 | 63 | 0.020 |
Why?
|
| Caffeine | 1 | 2012 | 83 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 297 | 0.020 |
Why?
|
| Motivation | 1 | 2014 | 296 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 60 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 231 | 0.020 |
Why?
|
| Health Surveys | 1 | 2011 | 240 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 354 | 0.020 |
Why?
|
| Age of Onset | 1 | 2011 | 318 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2887 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 785 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2012 | 275 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 1899 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 872 | 0.020 |
Why?
|
| DNA | 1 | 2015 | 1311 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 161 | 0.020 |
Why?
|
| Switzerland | 1 | 2008 | 17 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 596 | 0.020 |
Why?
|
| Impulsive Behavior | 1 | 2012 | 288 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 22 | 0.020 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2008 | 19 | 0.020 |
Why?
|
| Dyspnea | 1 | 2008 | 76 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 506 | 0.020 |
Why?
|
| Anisotropy | 1 | 2008 | 63 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2008 | 186 | 0.020 |
Why?
|
| Models, Economic | 1 | 2008 | 62 | 0.020 |
Why?
|
| Affect | 1 | 2010 | 389 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 2008 | 59 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2008 | 149 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 662 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 983 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 467 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 2004 | 36 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1929 | 0.010 |
Why?
|
| Education, Medical, Graduate | 1 | 2006 | 402 | 0.010 |
Why?
|
| Patient Selection | 1 | 2004 | 682 | 0.010 |
Why?
|